Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (Q43500076)

24 November 2017

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (English)

1 reference

24 November 2017

1 reference

metastatic colon cancer

1 reference

1 reference

1

1 reference

24 November 2017

3

1 reference

24 November 2017

Sabine Tejpar

2

1 reference

24 November 2017

Domenica Mercadante

4

1 reference

24 November 2017

Tracey Teague

5

1 reference

24 November 2017

Bruno Wohlschlegel

6

1 reference

24 November 2017

Eric Van Cutsem

7

1 reference

24 November 2017

1 June 2011

1 reference

24 November 2017

1 reference

24 November 2017

6

1 reference

24 November 2017

3

1 reference

24 November 2017

133-145

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-011-0181-x

24 November 2017

0 references

cites work

Future of personalized medicine in oncology: a systems biology approach

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutation screening in colorectal cancer: From paper to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

21 January 2018

1 reference

12 December 2020

Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

12 December 2020

K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients

1 reference

12 December 2020

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

12 December 2020

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

1 reference

12 December 2020

10.1007/S11523-011-0181-X

Identifiers

DOI

1 reference

release_cdkl4ongxjhvhpy42jnm74xwt4

24 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cdkl4ongxjhvhpy42jnm74xwt4

24 November 2022

mapped directly with Wikidata item

1 reference